a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (NCT04053322) | UNICANCER | 2019-08-26 |
Track a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status automatically
Every clearance here is in the API, with alerts when new ones post.